FEATURES OF THE CLINICAL COURSE OF ODONTOGENIC PHLEGMONS OF MAXILLOFACIAL LOCATION IN PATIENTS WITH ISCHEMIC HEART DISEASE

Odontogenic phlegmons of maxillofacial localization make up from 30% to 50% of the total number of patients in maxillofacial hospitals. Systemic changes that contribute to the spread of infection can be observed in situations such as HIV/AIDS, decompensated diabetes mellitus, immunosuppression, alcoholism, or weakened conditions, including diseases of the cardiovascular system. Purpose of the study: to analyze the clinical course of odontogenic phlegmons of maxillofacial localization in patients with ischemic heart disease. A clinical examination of patients with phlegmons of maxillofacial localization on the background of ischemic heart disease was conducted for the period from 2022 to 2024. The following clinical indicators were examined: P1.1 body temperature; P1.2 pulse rate; P1.3 pain index on the VAS visual analog scale; P1.4 chewing dysfunction; P1.5 – swallowing dysfunction; P1.6 – speech dysfunction. The indicators were expressed in points – from 0 to 3 for P1.1, P1.2, P1.3 and from 0 to 1 point for indicators P1.4, P1.5, P1.6. When analyzing the dynamics of the indicator P1.1, its insignificant increase on the 3rd day of the postoperative period by an average of 0.5 points was noted, but on the 5th day – a decrease of 0.7 points, which indicates the transition of the reparative process to the 2nd phase. A similar situation was observed with regard to the dynamics of the indicator P1.2, which gradually decreased in the period from the 1st to the 5th day by an average of 0.55 points with a slight increase on the 7th day by 0.15 points. If on the first day we had an average score of 2.65 points and by the 5th day a significant small decrease of 0.5 points was recorded. When quercetin in tablet form was included in the conservative therapy, the general clinical indicators of patients with odontogenic phlegmons of maxillofacial localization on the background of ischemic heart disease were minimally better than the similar indicators of the control group, where the treatment was carried out according to standard protocols, starting from the 5th day of observation.